Efficacy and safety of DPP-1 inhibitors in bronchiectasis: a GRADE-assessed meta-analysis of randomized controlled trials
DPP-1 inhibitors reduce exacerbation frequency, delay time to first exacerbation, and improve respiratory symptoms in bronchiectasis without compromising safety. These findings support their role as a potential disease-modifying therapy in bronchiectasis management. Further long-term studies are warranted to confirm their sustained clinical benefit.
Authors
- Abdalhakim R. M. Shubietah (ORCID: https://orcid.org/0000-0002-8300-0262)
- ABDUL MUHSEN ABDEEN (ORCID: https://orcid.org/0009-0009-9232-2114)
- Mohamed Emara (ORCID: https://orcid.org/0000-0003-1331-6365)
- Mohamed Ellebedy
- Ameer Awashra (ORCID: https://orcid.org/0009-0002-5122-8200)
- Ahmed Emara (ORCID: https://orcid.org/0009-0001-2718-8627)
- Mohamed S. Elgendy (ORCID: https://orcid.org/0000-0003-3080-2875)
- Omar F. Abbas
- Fadi Safi
- Ahmed Diaa
Institutions
- An-Najah National University (PS)
- Al-Azhar University (EG)
- Tanta University (EG)
- Advocate Illinois Masonic Medical Center (US)
- Marshall University (US)
- University of Toledo (US)
- Sohag University (EG)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s12931-025-03407-2
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52